Join Us at CPHI China 2025! SINOPEG's booth no. W4F66 Exciting news! CPHI China 2025 is just around the corner, taking place June 24–26 at the Shanghai New International Expo Centre. SINOPEG will be showcasing cutting-edge drug delivery system (DDS) solutions at Booth W4F66. As your trusted partner in specialty chemicals and advanced drug delivery systems, we’re eager to share innovations that drive industry progress. Why visit us? Explore our latest portfolio of PEG derivatives, lipids, and custom synthesis services Discuss tailored solutions for your R&D and manufacturing challenges Connect face-to-face with our technical experts We warmly welcome friends, partners, and industry peers from around the globe to drop by! Let’s collaborate to shape the future of pharma.  Dates: June 24–26, 2025 Venue: Shanghai New International Expo Centre Our Booth: W4F66 (Hall W4) Ready to meet? Simply stop by! 

Monday Motivation: Let's Kickstart TIDES USA 2025! The wait is almost over—TIDES USA 2025 begins! As the leading event for oligonucleotide and peptide innovation, this is the place to connect with industry pioneers and explore breakthroughs shaping the future of therapeutics. SINOPEG is excited to join the conversation at Booth #613! Whether you're looking to discuss cutting-edge PEGylation technologies, lipid technologies, explore customized solutions, or simply network with our team, we're here to collaborate and inspire. Why stop by? Discover our latest advancements in drug delivery systems. Connect with experts driving precision and innovation. Explore partnerships to accelerate your next-gen therapies. Pro tip: Book a meeting with us in advance or drop by anytime—we'd love to brainstorm how we can support your goals! Let's make this week transformative. See you at Booth #613! https://lnkd.in/gpSNd5si #TIDESUSA2025 #Oligonucleotides #PeptideTherapeutics #DrugDelivery #PEGylation #SINOPEG #InnovationInHealthcare

Mol Ther. 2022 Sep 7;30(9):3078-3094.   doi: 10.1016/j.ymthe.2022.07.007.   Epub 2022 Jul 12. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells Abstract mRNA vaccines have recently proved to be highly effective against SARS-CoV-2.   Key to their success is the lipid-based nanoparticle (LNP), which enables efficient mRNA expression and endows the vaccine with adjuvant properties that drive potent antibody responses.   Effective cancer vaccines require long-lived, qualitative CD8 T cell responses instead of antibody responses.   Systemic vaccination appears to be the most effective route, but necessitates adaptation of LNP composition to deliver mRNA to antigen-presenting cells.   Using a design-of-experiments methodology, we tailored mRNA-LNP compositions to achieve high-magnitude tumor-specific CD8 T cell responses within a single round of optimization.   Optimized LNP compositions resulted in enhanced mRNA uptake by multiple splenic immune cell populations.   Type I interferon and phagocytes were found to be essential for the T cell response.   Surprisingly, we also discovered a yet unidentified role of B cells in stimulating the vaccine-elicited CD8 T cell response.   Optimized LNPs displayed a similar, spleen-centered biodistribution profile in non-human primates and did not trigger histopathological changes in liver and spleen, warranting their further assessment in clinical studies.   Taken together, our study clarifies the relationship between nanoparticle composition and their T cell stimulatory capacity and provides novel insights into the underlying mechanisms of effective mRNA-LNP-based antitumor immunotherapy. Keywords: LNP;   cancer;   design-of-experiments methodology;   extrahepatic delivery;   immunotherapy;   mRNA;   vaccination. Excipient for DNA/RNA Delivery Lipid For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

Review J Nanobiotechnology. 2022 Jun 14;20(1):276. doi: 10.1186/s12951-022-01478-7. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects Abstract In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high efficiency, safety and adverse effects challenges due to the uncontrolled immune responses and inappropriate pharmacological interventions could limit this tremendous efficacy. The current study reveals the interplay of immune responses with LNP compositions and characterization and clarifies the interaction of mRNA-LNP therapeutics with dendritic, macrophages, neutrophile cells, and complement. Then, pharmacological profiles for mRNA-LNP delivery, including pharmacokinetics and cellular trafficking, were discussed in detail in cancer types and infectious diseases. This review study opens a new and vital landscape to improve multidisciplinary therapeutics on mRNA-LNP through modulation of immunopharmacological responses in clinical trials. Keywords: Dendritic cell; Immune system; Immunogenicity; Lipid nanoparticles; Pharmacologic response; Toll-like receptor; mRNA delivery. Excipient for DNA/RNA Delivery Lipid For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

Review Adv Mater. 2023 Dec;35(51):e2303261. doi: 10.1002/adma.202303261. Epub 2023 Nov 1. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy Abstract Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of coronavirus disease 2019 (COVID-19) mRNA vaccines (Comirnaty and Spikevax). To meet the therapeutic purpose, it is required that mRNA must enter the target cells and express sufficient proteins. Therefore, the development of effective delivery systems is necessary and crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle that has indeed accelerated mRNA applications in humans, as several mRNA-based therapies have already been approved or are in clinical trials. In this review, the focus is on mRNA-LNP-mediated anticancer therapy. It summarizes the main development strategies of mRNA-LNP formulations, discusses representative therapeutic approaches in cancer, and points out current challenges and possible future directions of this research field. It is hoped that these delivered messages can help further improve the application of mRNA-LNP technology in cancer therapy. Keywords: cancer therapy; lipid nanoparticles; mRNA delivery; mRNA therapeutics. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

We are excited to announce that XIAMEN SINOPEG BIOTECH CO., LTD. will be exhibiting at BIOCHINA 2025! Join us from March 12-15 in Suzhou to explore our latest innovations in Drug Delivery System (DDS). Let's connect, collaborate, and drive the future of biotech together! Booth: SD3-035 Date: March 12-15, 2025 Location: Suzhou International Expo Center Looking forward to meeting partners, clients, and industry leaders! Let’s innovate together. Follow BIOCHINA for more updates: BIOCHINA LinkedIn Homepage #BIOCHINA2025 #Biotech #LifeScienc

Int J Mol Sci. 2022 Oct 3;23(19):11707. doi: 10.3390/ijms231911707. PEG2-Induced Pyroptosis Regulates the Expression of HMGB1 and Promotes hEM15A Migration in Endometriosis Abstract Endometriosis (EMS) is a common gynecological disease. Prostaglandin E2 (PGE2), which induces chronic pelvic inflammation and cell pyroptosis, a form of programmed cell death based on inflammasome activation, are involved in EMS, but the extent of their involvement and roles remain unclear. The present study aimed to evaluate PGE2-induced pyroptosis in EMS and the influence of PGE2 in EMS progression. Using western blotting, it was found that the expressions of PGE2 and pyroptosis-related proteins (NLRP3, cleaved caspase-1, interleukin (IL)-1β and IL-18) were higher in EMS tissues than in normal endometrial tissues. The levels of PGE2, IL-1β, and IL-18 in the serum of patients with EMS and cell culture fluids were also detected. Using the transwell assay, we verified that PGE2 promoted hEM15A migration via the NLRP3/caspase-1 pyroptotic pathway, and PGE2-induced pyroptosis upregulated the expressions of high mobility group box 1 (HMGB1), E-cadherin, and vimentin. Immunohistochemistry analysis confirmed that PGE2-induced pyroptosis contributed to EMS invasion. These results suggest that PGE2-induced pyroptosis affects the progression of EMS by changing the migration ability of pyroptotic cells and upregulating the expression of HMGB1, E-cadherin, and vimentin. Our findings provide crucial evidence for new treatment pathways and use of anti-inflammatory drugs in EMS. Keywords: PGE2; cell migration; endometriosis; pyroptosis. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

ACS Appl Bio Mater. 2021 Mar 15;4(3):2769-2780. doi: 10.1021/acsabm.1c00004. Epub 2021 Mar 2. Injectable and Degradable PEG Hydrogel with Antibacterial Performance for Promoting Wound Healing Abstract Injectable and degradable PEG hydrogel was prepared via Michael-type addition between cross-linking monomer 4-arm-PEG-MAL and two cross-linkers of hydrolysis degradable PEG-diester-dithiol and non-degradable PEG-dithiol, and it had a porous structure with the uniform pore size. The biocompatibility assays in vitro indicated that PEG hydrogel had excellent biocompatibility and can be degraded naturally without leading to any negative impact on cells. The results of antibacterial experiments showed that PEG hydrogel can inhibit the growth of bacteria. Furthermore, the Cell Counting Kit-8 (CCK-8) assay, LIVE/DEAD cell staining, and scratch healing experiments proved that PEG hydrogel can promote cell proliferation and migration, which had been further confirmed in in vivo experiments on the rat wound models. All experimental results demonstrated that PEG hydrogel is an injectable antibacterial dressing, which can promote the process of wound healing and has great potential in the field of wound healing. Keywords: PEG hydrogel; antibacterial; degradable; injectable; wound healing. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com